Positron Corporation's Attrius PET Scanner Now Utilized In Alzheimer's Imaging With Amyvid Agent
Published: Aug 20, 2012
CHICAGO, Aug. 16, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) a leading molecular imaging healthcare company is pleased to announce the use of their Attrius system at Caring Heart and Brain Imaging Inc., of Manasquan, New Jersey, which now offers Amyvid PET scans to identify the presence of plaque in the brain, which has been shown to be a precursor to Alzheimer's disease.
Amyvid (Florbetapir F-18 Injection) is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
Alzheimer's disease is the most common cause of dementiaa group of brain disorders that cause progressive loss of intellectual and social skills, severe enough to interfere with day-to-day life. In Alzheimer's disease, brain cells degenerate and die, causing a steady decline in memory and mental function.
"Current AD medications and management strategies can temporarily improve symptoms, maximize function and maintain independence and we are pleased that our Attrius PET system could possibly help with the identification and management of this disease," stated Joseph Oliverio, Chief Technology Officer and Director of PET Clinical Programs of Positron.
Lorraine Catalano, Imaging Director of Caring Heart stated, "Alzheimer's disease can now be diagnosed several years before the onset of symptoms. Early detection can lead to innovative programs designed to treat memory loss. This alternative can make the difference between a life of constant hardship or one that is fulfilled and remains on top of its game."
Anthony Deluca, M.D., Medical Director of Caring Heart and Brain Imaging stated, "We are pleased to be the first in New Jersey to offer this service. We are also delighted with the image quality that the Attrius scanner provides."
Positron Corporation is a leading molecular imaging healthcarecompany vertically integrating all the segments of nuclear cardiologyproviding an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.
About Caring Heart and Brain Imaging:
Caring Heart and Brain Imaging Inc. is the first dedicated cardiac and brain PET imaging facility in the State of New Jersey, located at 2414 Highway 35N in Manasquan, NJ. Along with an expert staff dedicated to patient comfort and peace of mind, we bring over 30 years of experience: Anthony Deluca, MD and Lorraine Catalano, CNMT, have been active in the medical field as family practice specialist and nuclear medicine technologist, respectively. Dr. Deluca has developed a close referring relationship to his cardiology and neurology colleagues and Lorraine Catalano has a shared perspective as a technologist performing Nuclear Cardiology and Nuclear Brain scans for more than 15 years. Debra Schneider directs all facility procedures with expertise and compassion and our patient coordinator, Lil Hogan, always greets patients with respect and consideration. Together this team ensures that Caring Heart and Brain's commitment to patient care is maintained and fulfilled. Patients will be imaged in a warm and comfortable environment, like no other. We will take care of you like family and scan you with caring hands. www.chci.biz
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation